Abstract: Matrix particles containing one or more matrix materials and one or more hydrophobic active agents, agglomerated particles made therefrom, fibrous structures containing such matrix particles and/or agglomerated particles, and processes for making same are provided.

Abstract: Disclosed is a topical composition comprising: (i) an antimicrobial active which is at least one of piroctone, caprylhydroxamic acid, benzohydroxamic acid, or piroctone olamine; and (ii) norbraylin. Also disclosed is a non-therapeutic method of providing topical antimicrobial benefit on a topical surface of a human or animal body comprising a step of applying a safe and effective amount of the topical composition.

Abstract: The disclosure provides for solid products configured for oral use, the products including a carrier material; a releasable material; and wherein the releasable material is combined with the carrier material such that the releasable material is configured for sustained release from the solid product when the solid product is positioned in an oral cavity for a consumer. In another aspect, the disclosure provides for a method of preparing a solid product for oral use, the method comprising providing a releasable material in sprayable form; providing a pouch formed of a fibrous material; and spraying a flavor component onto a least a portion of the pouch one or both of before and after filling the pouch with the oral composition.

Abstract: The present disclosure provides antimicrobial coating compositions that are used to form residual antimicrobial coatings on medical implements and medical devices including the components of medical equipment such as CPAP/BiPAP machines. Antimicrobial coating compositions comprise at least one of an organosilane (R1O)3Si—R2—Z, an organic amine R9R10R11N, a titanium (IV) species, a 1,2-diol, an ?-hydroxy acid, a ?-hydroxy acid, and an organosilane grafted parylene polymer, wherein R1 is H, alkyl, substituted alkyl, aryl or substituted aryl, R2 is a bivalent linker, Z is a nucleophile, leaving group, or quaternary nitrogen substituent, and R9, R10, and R11 are independently H, alkyl, substituted alkyl, aryl, substituted aryl or cyclic.

Abstract: The present invention relates to the use of iminooxothiazolidine derivatives for preventing or treating hair growth disorders. The iminooxothiazolidine derivatives may be formulated as compositions suitable for either the systemic administration or the local application to the scalp.

Abstract: Disclosed are compositions and related methods of recapitulating bone marrow stroma using scaffold materials (e.g., a porous alginate hydrogel scaffold) containing one or more cellular differentiation factors, and one or more growth factors. Such methods and compositions promote the formation of an ectopic nodule or site that can improve transplanted cell engraftment and selectively drive the development of lymphocytes and the reconstitution of the adaptive immunity after hematopoietic stem cell transplant.

Abstract: The invention relates to compositions and methods containing hemp and/or Cannabis-derived cannabidiol (CBD) for topical use in treating female sexual dysfunction induced by antidepressants, including, e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin/norepinephrine reuptake inhibitors (SNRIs), and other anti-depressants.

Abstract: Systems and methods of use of chlorine dioxide in controlled environmental agriculture settings and postharvest applications are provided. A method can comprise application of gaseous chlorine dioxide at a level effective to prevent microbial proliferation in a setting containing growing plants. A system can comprise a chemical microorganism control agent dispersal system, an airborne microorganism detection system, and a cultivation environment monitor system.

Abstract: Oral compositions and methods of use thereof are provided herein. The oral compositions comprise a first component comprising at least one Eh-raising compound and a pharmaceutically acceptable carrier, and a second component comprising at least one zinc compound, an anti-microbial agent and a pharmaceutically acceptable carrier.

Abstract: The present disclosure provides a composition for submucosal injection including a divalent cation and an oligosaccharide obtained by exposing powdered polysaccharides to irradiation, heat, ultrasound, or ultraviolet radiation. The composition may be provided as a single solution; or the divalent cation and the oligosaccharide may be separately packaged, with the divalent cation being provided in solution form and the oligosaccharide being provided in powder form. The divalent cation may be 0.1-0.5% w/v of Ca2+, Mg2+, Fe2+, Cu2+, Ba2+, Zn2+, or any combination thereof. The oligosaccharide may be 0.5-2% w/v of degraded sodium alginate, degraded xanthan gum, degraded dextran, degraded welan gum, degraded gellan gum, degraded diutan gum, or any combination thereof. When the divalent cation is in contact with the oligosaccharide, viscosity of the composition is greater than 1000 cP, and injection pressure of the composition falls within a range of 2.5-4 kgf.

Abstract: This method for producing a freeze-dried formulation including an amorphous form of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide sodium salt is useful as a method for producing a freeze-dried formulation having uniform quality.

Abstract: The invention encompasses formulations and methods for the production thereof that permit the delivery of concentrated protein solutions. The inventive methods can yield a lower viscosity liquid formulation or a higher concentration of therapeutic or nontherapeutic proteins in the liquid formulation, as compared to traditional protein solutions.

Abstract: Compositions, devices and methods employing therapeutic concentrations of a triptan for treatment of migraine are described. Also described are methods and apparatuses for delivery of zolmitriptan for achieving a Tmax as quick as 2 minutes and not later than 30 minutes in the majority of subjects.

Abstract: The invention encompasses formulations and methods for the production thereof that permit the delivery of concentrated protein solutions. The inventive methods can yield a lower viscosity liquid formulation or a higher concentration of therapeutic or nontherapeutic proteins in the liquid formulation, as compared to traditional protein solutions.

Abstract: The present invention relates to an agent for preventing myopia, treating myopia, and/or preventing myopia progression, comprising tiotropium as an active ingredient.

Abstract: The invention provides topical compositions and methods for using the compositions. The compositions can be used for the treatment of fibrotic or connective tissue disorders involving scarring, sub-dermal plaque accumulations, or fibrosis of muscle tissue. The disorders can be painlessly treated by the topical application of a composition described herein. One or more calcium channel blocker agents can serve as an active ingredient of the compositions, optionally in combination with, for example, one or more of emu oil and superoxide dismutase. The composition can further include pharmaceutically acceptable carriers that can facilitate the non-invasive transdermal delivery of the active(s) to subdermal sites.

Abstract: The present invention is a sterile peritoneal dialysis fluid, including an acidic first liquid containing 60.0 to 94.0 g/L of icodextrin and 0 to 2.34 g/L of sodium chloride, and an alkaline second liquid containing an alkaline pH regulator, in which the first liquid after sterilization has a pH of 5.0 to 5.5, the second liquid after sterilization has a pH of 6.5 to 7.5, and a mixture of the first liquid and the second liquid after sterilization has a pH of 6.0 to 7.5. The present invention can provide a peritoneal dialysis fluid containing icodextrin, in which the stability of icodextrin during the heat sterilization and the subsequent storage can be improved to the maximum, and the pH of the peritoneal dialysis fluid is close to the physiological range.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hair loss, a health functional food composition or a cosmetic composition, including a specific compound or a pharmaceutically acceptable salt thereof as an active ingredient, wherein the compound exhibits an excellent hair growth recovery effect in hair follicle tissues in which hair growth is inhibited without cytotoxicity, and thus hair loss can be more effectively prevented, improved, or treated.

Abstract: The present disclosure relates to a soluble microneedle and a filler composition with an excellent anti-wrinkle effect. Using the microneedle according to the present disclosure, crosslinked hyaluronic acid (hyaluronic acid filler material) can be intradermally or subcutaneously administered by a simple method, and a swelling property of the crosslinked hyaluronic acid is improved after administration, thereby exhibiting the excellent anti-wrinkle effect.

Abstract: An oral amphetamine extended release liquid suspension is described. The compositions contain a combination of an uncoated amphetamine-cation exchange resin complex, a barrier coated amphetamine-cation exchange resin complex-matrix, and an uncomplexed amphetamine, wherein one or more of these components contains blends of different forms of amphetamines. Either the modified release coated and/or the uncoated amphetamine-cation exchange resin complex may have two forms of amphetamine in a complex with a single cation exchange resin. Following administration of a single dose of the composition, a therapeutically effective amount of amphetamine is reached by about one hour and the composition provides at least a thirteen hour effect post-dose.